GEP20125629B - Novel antiproliferation antibodies - Google Patents

Novel antiproliferation antibodies

Info

Publication number
GEP20125629B
GEP20125629B GEAP200711322A GEAP2007011322A GEP20125629B GE P20125629 B GEP20125629 B GE P20125629B GE AP200711322 A GEAP200711322 A GE AP200711322A GE AP2007011322 A GEAP2007011322 A GE AP2007011322A GE P20125629 B GEP20125629 B GE P20125629B
Authority
GE
Georgia
Prior art keywords
novel
antiproliferation antibodies
antibodies
antiproliferation
complementarities
Prior art date
Application number
GEAP200711322A
Other languages
English (en)
Inventor
Liliane Goetsch
Nathalie Corvaia
Jean-Francois Haeuw
Cedric Bes
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of GEP20125629B publication Critical patent/GEP20125629B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
GEAP200711322A 2006-11-24 2007-11-23 Novel antiproliferation antibodies GEP20125629B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0610329A FR2909092B1 (fr) 2006-11-24 2006-11-24 Nouveaux anticorps anti-proliferation

Publications (1)

Publication Number Publication Date
GEP20125629B true GEP20125629B (en) 2012-09-10

Family

ID=37903981

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP200711322A GEP20125629B (en) 2006-11-24 2007-11-23 Novel antiproliferation antibodies

Country Status (27)

Country Link
US (2) US8071730B2 (https=)
EP (1) EP2074148A1 (https=)
JP (1) JP2010509931A (https=)
KR (1) KR20090088878A (https=)
CN (1) CN101535344B (https=)
AU (1) AU2007324509B2 (https=)
BR (1) BRPI0719323A2 (https=)
CA (1) CA2670039A1 (https=)
CL (1) CL2007003357A1 (https=)
CR (1) CR10788A (https=)
CU (1) CU23792A3 (https=)
EC (1) ECSP099341A (https=)
FR (1) FR2909092B1 (https=)
GE (1) GEP20125629B (https=)
GT (1) GT200900126A (https=)
IL (1) IL198744A0 (https=)
MA (1) MA30891B1 (https=)
MX (1) MX2009005293A (https=)
NI (1) NI200900079A (https=)
NO (1) NO20092360L (https=)
NZ (1) NZ576174A (https=)
RU (1) RU2451689C2 (https=)
SA (1) SA07280637B1 (https=)
TN (1) TN2009000194A1 (https=)
TW (1) TW200829602A (https=)
UA (1) UA99602C2 (https=)
WO (1) WO2008062063A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
EP2313435A4 (en) 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
CN102596249A (zh) * 2009-10-30 2012-07-18 默沙东公司 Ax1和ax189 pcsk9拮抗剂和变体
EA201390472A1 (ru) * 2010-10-29 2014-02-28 Иммьюноджен, Инк. Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
EP2455403A1 (en) 2010-11-23 2012-05-23 Pierre Fabre Medicament Homogeneous humanized antibodies against JAM-A that inhibit proliferation
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20130287790A1 (en) * 2012-03-30 2013-10-31 The Board Of Trustees Of The Leland Standford Junior University Use of jam-a in diagnosing and treating leukemia
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
ES2702315T3 (es) 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
KR20150097304A (ko) 2014-02-18 2015-08-26 삼성전자주식회사 항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체
CA3015619A1 (en) 2016-03-01 2017-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)
TWI767915B (zh) 2016-06-27 2022-06-21 加州大學董事會 Ror-1與btk拮抗劑的組合
US12084495B2 (en) 2016-08-03 2024-09-10 Nextcure, Inc. Compositions and methods for modulating LAIR signal transduction
CN109022366A (zh) * 2018-08-16 2018-12-18 江南大学 一株分泌抗左旋咪唑单克隆抗体的杂交瘤细胞株及其应用
EP4041392A1 (en) 2019-10-08 2022-08-17 Nectin Therapeutics Ltd. Antibodies against the poliovirus receptor (pvr) and uses thereof
CN114740108B (zh) * 2022-03-28 2023-07-14 天津键凯科技有限公司 一种聚合物修饰抗体类药物的修饰度的测定方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604470D0 (sv) * 1996-12-04 1996-12-04 Tamas Bartfai Konsulting Ab Transmembrane component of tight junction
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20030171568A1 (en) * 1998-09-16 2003-09-11 Avi Ashkenazi Use of A33 antigens and JAM-IT
DK1069185T3 (da) * 1998-04-03 2011-06-27 Chugai Pharmaceutical Co Ltd Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof
JP4836329B2 (ja) * 1999-03-11 2011-12-14 メルク セローノ エス．エイ． 血管接着分子およびその機能の調節
WO2005060457A2 (en) * 2003-12-04 2005-07-07 Pdl Biopharma, Inc. Treatment of inflammatory bowel diseases with anti-ip-10 antibodies
WO2006008076A2 (en) * 2004-07-16 2006-01-26 Universita Degli Studi Di Milano Methods and agents stimulating the immune response
EP1888639A1 (en) * 2005-05-12 2008-02-20 Oncotherapy Science, Inc. Methods for damaging cells using effector function of anti-dsc2 antibody
WO2007127476A2 (en) * 2006-04-28 2007-11-08 Oregon Health & Science University Monoclonal antibodies specific for pancreatic endocrine, exocrine or ductal cell

Also Published As

Publication number Publication date
US20100092455A1 (en) 2010-04-15
NZ576174A (en) 2012-03-30
NI200900079A (es) 2010-11-10
GT200900126A (es) 2011-09-02
WO2008062063A1 (en) 2008-05-29
CA2670039A1 (en) 2008-05-29
TN2009000194A1 (en) 2010-10-18
BRPI0719323A2 (pt) 2014-02-04
CR10788A (es) 2009-06-23
US8071730B2 (en) 2011-12-06
SA07280637B1 (ar) 2012-04-11
RU2009123409A (ru) 2010-12-27
CN101535344A (zh) 2009-09-16
EP2074148A1 (en) 2009-07-01
AU2007324509B2 (en) 2013-01-17
ECSP099341A (es) 2009-06-30
TW200829602A (en) 2008-07-16
CU23792A3 (es) 2012-03-15
MA30891B1 (fr) 2009-11-02
KR20090088878A (ko) 2009-08-20
CN101535344B (zh) 2013-10-16
UA99602C2 (ru) 2012-09-10
JP2010509931A (ja) 2010-04-02
US20120156191A1 (en) 2012-06-21
MX2009005293A (es) 2009-08-07
NO20092360L (no) 2009-08-11
CL2007003357A1 (es) 2008-04-04
FR2909092B1 (fr) 2012-10-19
RU2451689C2 (ru) 2012-05-27
HK1132752A1 (en) 2010-03-05
AU2007324509A1 (en) 2008-05-29
IL198744A0 (en) 2010-02-17
FR2909092A1 (fr) 2008-05-30

Similar Documents

Publication Publication Date Title
GEP20125629B (en) Novel antiproliferation antibodies
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
NZ627103A (en) Specific binding proteins and uses thereof
NZ594480A (en) Methods and compositions for diagnosis and treatment of cancer
NZ599405A (en) Targeted binding agents against b7-h1
FI3389699T3 (fi) Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja
MX2009006891A (es) Anticuerpos cd44.
GEP20125594B (en) Sclerostin binding agents
GEP20125517B (en) Humanized monoclonical antibodies to hepatocyte growth factor
EA200700225A1 (ru) Аналоги тетрапептида
EA201070595A1 (ru) Низкомолекулярные миристатные ингибиторы тирозинкиназы bcr-abl и способы их применения
AU2010220421A8 (en) Antibodies against a proliferating inducing ligand (APRIL)
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
RU2014108049A (ru) Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
MX2010005022A (es) Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas.
TNSN08548A1 (en) Prlr-specific antibody and uses thereof
AU2006226733A8 (en) Antibodies against CD38 for treatment of multiple myeloma
RU2012137498A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
NZ599193A (en) Siglec 15 antibodies in treating bone loss-related disease
RU2014108045A (ru) Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
RU2014108043A (ru) Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
NZ610091A (en) Antibodies
CY1115572T1 (el) Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
NZ717847A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof